Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and improves survival in patients with non-small-cell lung cancer. We report 2 patients with extensive lytic bony metastasis in the spine and pelvis secondary to advanced pulmonary adenocarcinoma who were treated with gefitinib and had remarkable bone formation in the lytic bone lesions in the spine and pelvis. Surgery for stabilisation was avoided.
WuC, LiYL, WangZM, LiZ, ZhangTX, WeiZ. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer2007;57:359–64.
2.
MokTS, WuYL, ThongprasertS, YangCH, ChuDT, SaijoN. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Eng J Med2009;361:947–57.
3.
LangeT, Muller-TidowC, ServeH, HoffknechtP, BerdelWE, ThomasM. First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer. Oncol Rep2005;14:1539–42.
4.
TokuhashiY, MatsuzakiH, OdaH, OshimaM, RyuJ. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976)2005;30:2186–91.
5.
TomitaK, KawaharaN, KobayashiT, YoshidaA, MurakamiH, AkamaruT. Surgical strategy for spinal metastases. Spine (Phila Pa 1976)2001;26:298–306.
6.
FisherCG, DiPaolaCP, RykenTC, BilskyMH, ShaffreyCI, BervenSH. A novel classification system for spinal instability in neoplastic disease: An evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976)2010;35:E1221–9.
7.
NormannoN, De LucaA, AldinucciD, MaielloMR, MancinoM, D'AntonioA. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: Implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer2005;12:471–82.
8.
NormannoN, GullickWJ. Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: Different mechanisms of action for a novel therapeutic application?Endocr Relat Cancer2006;13:3–6.
9.
MirelsH. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res1989;249:256–64.
